for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sarepta says FDA delays decision on muscle-wasting disorder drug

(Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had delayed a decision on its lead drug for a rare muscle-wasting disorder.

The FDA has delayed the decision to May 26 from late February, the company said.

The drug is designed to treat a subset of patients with Duchenne muscular dystrophy.

The agency in late January postponed a meeting of its advisory panel to review Sarepta’s drug due to inclement weather forecast for Washington DC.

Reporting by Ankur Banerjee in Bengaluru; Editing by Kirti Pandey

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up